Abstract
Twelve biopharmaceuticals gained marketing approval in the US and EU in 2004. Antibody-based products represented the single largest product category and cancer, the most common indication.
| Original language | English |
|---|---|
| Pages (from-to) | 58-65 |
| Number of pages | 8 |
| Journal | BioPharm International |
| Volume | 18 |
| Issue number | 5 |
| Publication status | Published - May 2005 |
